Aug 3, 2025, 20:04
How the Latest Evidence Is Used in EGFR-Mutated NSCLC Treatment – NCODA
NCODA shared a post on LinkedIn:
“EGFR mutations drive nearly a third of NSCLC cases, with prevalence as high as 50% in some populations.
This World Lung Cancer Day, explore how the latest evidence, including results from FLAURA2 and MARIPOSA, is guiding the use of next‑generation TKIs and combination regimens to extend progression‑free survival beyond first‑line resistance.
Read the full article.”
More posts featuring NCODA on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 3, 2025, 20:04
Aug 3, 2025, 19:45
Aug 3, 2025, 19:32
Aug 3, 2025, 19:26
Aug 3, 2025, 19:18
Aug 3, 2025, 18:06